← All indications
Leukemia, Myelomonocytic, Chronic
A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
Drugs by status
Approved for this indication (2)
Phase 3 trials (29)
- tioguanine
- urea
- epoetin
- busulfan
- lenalidomide
- glasdegib
- imatinib
- naltrexone
- guadecitabine
- aldesleukin
- idarubicin
- mbg453
- pevonedistat
- allogeneic hematopoietic stem cells
- sch66336
- cyclophosphamide
- daunorubicin
- Anti-thymocyte Globulin (Rabbit)
- fludarabine
- etoposide
- sargramostim
- cytarabine
- rigosertib
- asparaginase
- nilotinib
- asciminib
- calcium phosphate
- cedazuridine
- imm01
Phase 2 trials (115)
- e-6201
- fluorothymidine
- cladribine
- thalidomide
- methylprednisolone
- lysergic acid diethylamide
- allogeneic natural killer cells
- amsacrine
- atezolizumab
- Eprenetapopt
- cusatuzumab
- mk-1775
- sorafenib
- venetoclax
- canakinumab
- cb-839
- temsirolimus
- cfi-400945
- clofarabine
- cobimetinib
- quizartinib
- prednisone
- selinexor
- e7820
- eltrombopag
- entinostat
- ff-10501-01
- olutasidenib
- gemcitabine
- tacrolimus
- +85 more
Phase 1 trials (81)
- prexasertib
- afatinib
- amg 176
- apg-115
- olaparib
- abaloparatide
- becatecarin
- belinostat
- talazoparib
- bpx-501
- bryostatin
- cd25-depleted peripheral blood mononuclear cell
- cwp232291
- dec-205/ny-eso-1 fusion protein cdx-1401
- dtgm fusion protein
- enzalutamide
- gemtuzumab ozogamicin
- fluorouracil
- h3b-8800
- hum-195/rgel
- idelalisib
- in111 anti-cd45 monoclonal antibody bc8
- lenzilumab
- pembrolizumab
- lenvatinib
- msk-2206
- palbociclib
- panobinostat
- ibrutinib
- xk469
- +51 more
Organizations
Organization Involved with Phase 3 Indications (11)
Organization Involved with Phase 2 Indications (89)
- S*BIO
- Incyte
- Eisai
- Ambit Biosciences
- Celgene
- Bristol-Myers Squibb
- Astellas
- Genentech
- Genzyme
- Pfizer
- Aprea Therapeutics AB
- Bayer
- BioLite, Inc.
- IGF Oncology, LLC
- Kura Oncology, Inc.
- Sensei Pharmaceuticals, Inc.
- Teva
- Nerviano Medical Sciences
- TetraLogic Pharmaceuticals
- Stemline Therapeutics, Inc.
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- Vastra Gotaland Region
- Nordic MDS Group
- Aarhus University
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Case Western Reserve University
- University of London
- Harvard University
- Duke University
- +59 more
Organization Involved with Phase 1 Indications (24)
- Seattle Genetics
- AstraZeneca
- Pharmacyclics
- Eli Lilly
- Bellicum Pharmaceuticals
- CTI BioPharma
- Erimos Pharmaceuticals
- JW Pharmaceutical
- Regimmune Inc.
- Boehringer Ingelheim
- University of Pittsburgh
- AIDS Malignancy Consortium
- University of Maryland
- Wake Forest University
- Columbia University
- University of California, Davis
- Loxo Oncology
- University of North Carolina at Chapel Hill
- University of Alabama, Birmingham
- Washington University in St. Louis
- Alex's Lemonade Stand Foundation
- Humanigen
- Newave Pharmaceutical Inc
- Immune-Onc Therapeutics Inc